^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    POLQ inhibitor

    Related drugs:
    2ms
    ART6043C001: Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (clinicaltrials.gov)
    P1/2, N=220, Active, not recruiting, Artios Pharma Ltd | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Lynparza (olaparib) • ART6043
    3ms
    POLAR: Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Repare Therapeutics | Recruiting --> Active, not recruiting | N=52 --> 26
    Enrollment closed • Enrollment change
    |
    Lynparza (olaparib)
    3ms
    The Discovery of RP-2119: A Potent, Selective, and Orally Bioavailable Polθ ATPase Inhibitor. (PubMed, J Med Chem)
    Further optimization of potency and ADME properties led to the identification of RP-2119 with robust in vitro cellular activity in a wide range of HR-deficient cancer cell lines. In HR-deficient cell line- and patient-derived mouse xenografts, RP-2119 demonstrated strong synergy with the PARP inhibitor, olaparib, without exacerbating its hematological toxicity.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    Lynparza (olaparib) • RP-2119
    3ms
    Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=110, Recruiting, Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
    New P1 trial
    |
    Lynparza (olaparib)
    4ms
    SYN-818-101: Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRCA (Breast cancer early onset)
    6ms
    A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors (clinicaltrials.gov)
    P1/2, N=135, Recruiting, GlaxoSmithKline | Trial completion date: Nov 2029 --> Jun 2027 | Trial primary completion date: Dec 2027 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    Zejula (niraparib)
    6ms
    Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=228, Not yet recruiting, Danatlas Pharmaceuticals Co., Ltd
    New P1 trial
    8ms
    A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=390, Active, not recruiting, Artios Pharma Ltd | Trial completion date: Aug 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative
    |
    Talzenna (talazoparib) • Zejula (niraparib) • ART4215
    11ms
    Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=130, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lynparza (olaparib)
    1year
    POLAR: Phase 1 Trial of RP-3467 Alone and in Combination with Olaparib in Participants with Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=52, Recruiting, Repare Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Lynparza (olaparib)
    1year
    Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=130, Not yet recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P1 trial
    |
    Lynparza (olaparib)
    1year
    Phase I Study of SYN818 Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
    New P1 trial • Metastases
    |
    BRCA (Breast cancer early onset)